Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACR16 in Huntington's Disease
NCT00665223Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of pridopidine in Huntington's disease (HD), sponsored by Teva Pharmaceutical Industries Ltd.. Started Apr 2008; status: completed.
02
Drugs
pridopidine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT00665223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665223.